ECSP10010368A - Derivados de urea de tetrahidroquinoxalina, su preparación - Google Patents
Derivados de urea de tetrahidroquinoxalina, su preparaciónInfo
- Publication number
- ECSP10010368A ECSP10010368A EC2010010368A ECSP10010368A ECSP10010368A EC SP10010368 A ECSP10010368 A EC SP10010368A EC 2010010368 A EC2010010368 A EC 2010010368A EC SP10010368 A ECSP10010368 A EC SP10010368A EC SP10010368 A ECSP10010368 A EC SP10010368A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- group
- coor5
- nr6r7
- alkoxy
- Prior art date
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- -1 -O-halogenoalkyl Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a los compuestos que responden a la fórmula (I) en la que A representa un enlace, un átomo de oxígeno o un grupo -O-CH2- ; Ar1 representa un grupo fenilo o heteroarilo ; Ar2 representa un grupo fenilo, heteroarilo o heterocicloalquilo ; R1a,b,c y R2a,b,c representan un átomo de hidrógeno o de halógeno o un grupo alquilo, cicloalquilo, -alquil-cicloalquilo sustituido opcionalmente con uno o varios átomos de halógeno, -OR5 (hidroxi o alcoxi), hidroxi-alquilo, alcoxi alquilo, alcoxi-alcoxi, halógenoalquilo, -O-halógenoalquilo, oxo, -CO-alquilo, -CO-alquilo-NR6R7, CO halógenoalquilo, -COOR5, alquil COOR5, -O-alquil-COOR5, SO2-alquilo, SO2-cicloalquilo, SO2-alquil-cicloalquilo, SO2-alquilo-OR5, SO2-alquil-COOR5, SO2-alquil-NR6R7 SO2 halógenoalquilo, alquil-SO2-alquilo, -SO2-NR6R7, -SO2-alquil-O-alquil-OR5, CONR6R7, -alquil-CONR6R7 o O alquil NR6R7, o R1a, R 1b, R 1c están unidos respectivamente a R2a, R 2b, R 2c y al átomo de carbono al que están unidos y representan -O-alquil-O- ; R3 representa un átomo de hidrógeno o un grupo alquilo, R4 representa un átomo de hidrógeno o de halógeno o un grupo ciano, -OR5, hidroxi-alquilo, -COOR5, NR6R7, CONR6R7, SO2-alquilo o SO2-NR6R7, -NR6-COOR5, -NR6-COR5, -CO-NR6-alquil-OR5 ; R5, R6 y R7 representan un átomo de hidrógeno, un grupo alquilo o -alquil-fenilo, y R8 representa un átomo de hidrógeno, un grupo -SO2-alquilo o un grupo de fórmula -B-Het, en la que B puede estar ausente o representar un enlace, un átomo de oxígeno o un grupo -CO- o -SO2-(CH2)n con n igual a 0, 1 ó 2 y en la que Het representa un heteroarilo o un heterocicloalquilo sustituido opcionalmente con grupos alquilos, SO2-alquilos y -COOR5. Procedimiento de preparación y aplicación en terapéutica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0800429A FR2926817B1 (fr) | 2008-01-28 | 2008-01-28 | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
| FR0804521A FR2934858B1 (fr) | 2008-08-08 | 2008-08-08 | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
| PCT/FR2009/000083 WO2009112691A2 (fr) | 2008-01-28 | 2009-01-27 | Dérivés d'urée de tetrahydroquinoxaline, leur préparation et leur application en thérapeutique j |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010368A true ECSP10010368A (es) | 2010-08-31 |
Family
ID=41037885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010368A ECSP10010368A (es) | 2008-01-28 | 2010-07-23 | Derivados de urea de tetrahidroquinoxalina, su preparación |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8211892B2 (es) |
| EP (1) | EP2238126B1 (es) |
| JP (1) | JP2011510919A (es) |
| KR (1) | KR20100111308A (es) |
| CN (1) | CN101981026A (es) |
| AR (1) | AR070255A1 (es) |
| AU (1) | AU2009224546B2 (es) |
| BR (1) | BRPI0906567A2 (es) |
| CA (1) | CA2713367A1 (es) |
| CL (1) | CL2009000173A1 (es) |
| CO (1) | CO6290672A2 (es) |
| CR (1) | CR11596A (es) |
| DO (1) | DOP2010000230A (es) |
| EA (1) | EA201070895A1 (es) |
| EC (1) | ECSP10010368A (es) |
| IL (1) | IL207195A (es) |
| MA (1) | MA32098B1 (es) |
| MX (1) | MX2010008290A (es) |
| NI (1) | NI201000130A (es) |
| PA (1) | PA8813701A1 (es) |
| PE (1) | PE20091323A1 (es) |
| TW (1) | TW200936136A (es) |
| UY (1) | UY31616A1 (es) |
| WO (1) | WO2009112691A2 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| CN102838599A (zh) | 2006-05-04 | 2012-12-26 | 贝林格尔.英格海姆国际有限公司 | 多晶型 |
| TW200936136A (en) * | 2008-01-28 | 2009-09-01 | Sanofi Aventis | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| EA022310B1 (ru) | 2008-12-23 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Солевые формы органического соединения |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| FR2948370B1 (fr) * | 2009-07-27 | 2013-04-05 | Sanofi Aventis | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
| FR2948369B1 (fr) * | 2009-07-27 | 2013-04-12 | Sanofi Aventis | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
| WO2011059021A1 (ja) * | 2009-11-11 | 2011-05-19 | 大日本住友製薬株式会社 | ８－アザビシクロ［３．２．１］オクタン－８－カルボキサミド誘導体 |
| NZ599298A (en) | 2009-11-27 | 2014-11-28 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| EP2518051A4 (en) * | 2009-12-22 | 2013-10-16 | Shionogi & Co | ADAMANTANAMINE DERIVATIVE |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| KR101519280B1 (ko) | 2010-08-09 | 2015-05-11 | 시오노기세이야쿠가부시키가이샤 | 아미노아다만탄카르바메이트 유도체의 제조 방법 |
| AU2011296926C1 (en) | 2010-09-03 | 2015-04-02 | Sumitomo Dainippon Pharma Co., Ltd. | Cyclic amide derivative |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| CA2841552C (en) | 2011-07-15 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| CN104379563B (zh) * | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| JP6043767B2 (ja) * | 2014-09-26 | 2016-12-14 | 株式会社アステム | 番組出力装置、補助情報管理サーバ、番組と補助情報の出力方法、及びプログラム |
| WO2016146602A1 (de) * | 2015-03-18 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Substituierte n-bicyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| KR102177304B1 (ko) * | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
| GB201818750D0 (en) * | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| CN109956958B (zh) * | 2019-04-02 | 2020-06-16 | 河北合佳医药科技集团股份有限公司 | 一种7-氨基-3-甲氧基甲基-3-头孢烯-4-羧酸合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| GB0505541D0 (en) * | 2005-03-17 | 2005-04-27 | Novartis Ag | Organic compounds |
| TW200811158A (en) * | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application |
| PE20080344A1 (es) * | 2006-06-27 | 2008-06-09 | Sanofi Aventis | Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1 |
| JP5223864B2 (ja) * | 2007-06-27 | 2013-06-26 | 大正製薬株式会社 | １１β−ＨＳＤ１阻害活性を有する化合物 |
| WO2009020140A1 (ja) * | 2007-08-06 | 2009-02-12 | Dainippon Sumitomo Pharma Co., Ltd. | アダマンチルウレア誘導体 |
| TW200936136A (en) * | 2008-01-28 | 2009-09-01 | Sanofi Aventis | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application |
-
2009
- 2009-01-23 TW TW098103125A patent/TW200936136A/zh unknown
- 2009-01-26 PE PE2009000105A patent/PE20091323A1/es not_active Application Discontinuation
- 2009-01-26 AR ARP090100229A patent/AR070255A1/es not_active Application Discontinuation
- 2009-01-27 PA PA20098813701A patent/PA8813701A1/es unknown
- 2009-01-27 BR BRPI0906567-9A patent/BRPI0906567A2/pt not_active IP Right Cessation
- 2009-01-27 WO PCT/FR2009/000083 patent/WO2009112691A2/fr not_active Ceased
- 2009-01-27 CA CA2713367A patent/CA2713367A1/fr not_active Abandoned
- 2009-01-27 JP JP2010543545A patent/JP2011510919A/ja active Pending
- 2009-01-27 EP EP09720707.0A patent/EP2238126B1/fr active Active
- 2009-01-27 MX MX2010008290A patent/MX2010008290A/es active IP Right Grant
- 2009-01-27 AU AU2009224546A patent/AU2009224546B2/en not_active Ceased
- 2009-01-27 EA EA201070895A patent/EA201070895A1/ru unknown
- 2009-01-27 CN CN2009801113945A patent/CN101981026A/zh active Pending
- 2009-01-27 KR KR1020107019130A patent/KR20100111308A/ko not_active Withdrawn
- 2009-01-28 UY UY031616A patent/UY31616A1/es not_active Application Discontinuation
- 2009-01-28 CL CL2009000173A patent/CL2009000173A1/es unknown
-
2010
- 2010-07-23 EC EC2010010368A patent/ECSP10010368A/es unknown
- 2010-07-25 IL IL207195A patent/IL207195A/en not_active IP Right Cessation
- 2010-07-26 NI NI201000130A patent/NI201000130A/es unknown
- 2010-07-26 US US12/843,124 patent/US8211892B2/en not_active Expired - Fee Related
- 2010-07-27 DO DO2010000230A patent/DOP2010000230A/es unknown
- 2010-07-27 CR CR11596A patent/CR11596A/es not_active Application Discontinuation
- 2010-07-28 CO CO10092048A patent/CO6290672A2/es not_active Application Discontinuation
- 2010-08-23 MA MA33110A patent/MA32098B1/fr unknown
-
2012
- 2012-05-30 US US13/483,710 patent/US8530657B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL207195A (en) | 2013-12-31 |
| EP2238126B1 (fr) | 2014-11-05 |
| PA8813701A1 (es) | 2009-09-17 |
| US20110009391A1 (en) | 2011-01-13 |
| IL207195A0 (en) | 2010-12-30 |
| CN101981026A (zh) | 2011-02-23 |
| TW200936136A (en) | 2009-09-01 |
| AU2009224546A1 (en) | 2009-09-17 |
| UY31616A1 (es) | 2009-08-31 |
| CR11596A (es) | 2010-09-13 |
| CA2713367A1 (fr) | 2009-09-17 |
| WO2009112691A2 (fr) | 2009-09-17 |
| NI201000130A (es) | 2010-12-17 |
| MA32098B1 (fr) | 2011-02-01 |
| JP2011510919A (ja) | 2011-04-07 |
| KR20100111308A (ko) | 2010-10-14 |
| CO6290672A2 (es) | 2011-06-20 |
| EA201070895A1 (ru) | 2011-04-29 |
| WO2009112691A3 (fr) | 2010-01-07 |
| DOP2010000230A (es) | 2010-08-31 |
| PE20091323A1 (es) | 2009-09-26 |
| US20120245148A1 (en) | 2012-09-27 |
| AU2009224546B2 (en) | 2014-01-30 |
| MX2010008290A (es) | 2010-08-18 |
| US8211892B2 (en) | 2012-07-03 |
| AR070255A1 (es) | 2010-03-25 |
| US8530657B2 (en) | 2013-09-10 |
| BRPI0906567A2 (pt) | 2015-07-07 |
| EP2238126A2 (fr) | 2010-10-13 |
| CL2009000173A1 (es) | 2010-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201000130A (es) | Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica. | |
| DOP2015000264A (es) | Derivados de azaadamantano y métodos de uso de los mismos | |
| CO6150144A2 (es) | Inhibidores de proteina tirosina fosfatasa humana y metodos de uso | |
| CR11547A (es) | Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica | |
| CO5700820A2 (es) | Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion en terapeutica | |
| CR20140180A (es) | Inhibidores macrocíclicos de serina proteasas de hepatitis c | |
| CO6150146A2 (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas su preparacion y su aplicacion en terapeutica | |
| AR047456A1 (es) | Derivados de amidas, procesos para su preparacion y uso como insecticidas | |
| ATE487608T1 (de) | Reversible thermochrome zusammensetzungen | |
| CO6220974A2 (es) | Derivados de indol 2-carboxamidas y de azaindol 2- carboxamidas sustituidos con un grupo silanilo su preparacion y su aplicacion en terapeutica | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| SV2004001555A (es) | Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos | |
| CR8889A (es) | Derivados de n-(1h-indolil)- 1h-indol-2- carboxamidas, su preparacion y su aplicacion en terapeutica | |
| UY32801A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| DOP2006000045A (es) | Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica | |
| GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
| CR9391A (es) | Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CR20110360A (es) | Derivados de 2-piridin-2-il-pirazol-3-(2h)-ona, su preparacion y su aplicacion en terapeutica | |
| ECSP078009A (es) | Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica | |
| ECSP10010672A (es) | NUEVOS DERIVADOS DE (PIPERAZINILO CON ENLACES PUENTE)-1-ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75 | |
| AR077425A1 (es) | Derivados de urea de tetrahidroquinoxalina, su preparacion y su uso en el tratamiento de enfermedades mediadas por la modulacion de la 11betahsd1 | |
| AR054583A1 (es) | Pantoprazol isotopicamente sustituido | |
| HRP20110780T1 (hr) | Aminoarilsulfonamidni spojevi i njihova upotreba kao ligandi 5-ht6 | |
| CR9693A (es) | Derivados de 5-piridazinil-1-azabiciclo[3.2.1]octano, su preparacion y su aplicacion en terapeutica | |
| CR10969A (es) | Derivados de azabicicloalcano, su preparacion y su aplicacion en terapeutica |